Named patient program

Managed Access Programs (MAPs): IKRIS Pharma Network

  • June 1, 2023
  • < 1 min read

When a patient has a seriously debilitating or life-threatening illness or disease and all available potential treatment options are exhausted and participation in a clinical trial is not possible, then the patient’s treating doctor may be able to request access to an investigational medicine before regulatory approval, provided this is allowed/permitted by applicable local laws and regulations.
IKRIS Pharma Network has a mechanism in place, known as “Managed Access Programs” through which certain potentially beneficial medicines can be legally made available to eligible patients, provided specific criteria and needs are met.

There is a wide range of terms that fall within Managed Access Programs, these include Compassionate Use (CU), Expanded Access (EA), Named Patient Program (NPP), Special Access Programs, and Individual Patient Requests amongst others. The use of these terms may differ from one place to another on behalf of local laws and regulations.

Requests for Managed Access must be submitted to IKRIS Pharma by the treating physician of the patient for whom the provision of a specific medicine is being requested. To submit a Managed Access request, please dial our TOLL-FREE: 1800-889-1064 or Call/WhatsApp: +91 9310090915.

If you wish to contact IKRIS Pharma you can use the Email address [email protected]. We will assess the request on behalf of the criteria and conditions mentioned above and further discuss it with the treating doctor.

IKRIS Pharma makes every effort to finalize the review process within 1 business day after receipt of the request. If approved, the Named Patient Supply process will be begun where the requesting doctor may need to provide some additional customer set-up and other relevant information.